Hyperammonemia is a clinical problem with severe consequences to the central nervous system. It is usually caused by liver disease, inherited metabolic disorders and various toxins. The main source of ammonia production is the bowel where ammonia is generated and it then diffuses into the portal blood. If the liver is unable to convert ammonia to urea due to an enzymatic defect or severe liver disease, the ammonia enters the systemic circulation intoxicating the brain. The goal of this project is to research a novel biological gene therapy for hyperammonemia aimed at the bowel. This approach seeks to deliver and maintain overexpression of genes encoding the first and second urea cycle enzymes within the bacterial flora of the gut. The hypothesis is that the expressed enzymes residing in an ammonia rich environment, will trap ammonia and convert it to citrulline rendering it non toxic. The gene encoding the first two enzymes of the urea cycle will be incorporated into a single plasmid expression vector overexpressing these genes simultaneously. E. coli carbamyl phosphate synthetase (CPS) large subunit carB, capable of converting ammonia to carbamyl phosphate with or without the gene encoding the small subunit, carA capable of hydrolyzing glutamine to ammonia and the human ornithine transcarbamylase (OTC), converting carbamyl phosphate to citrulline will be used to construct this expression vector. Various regulated promoters will be tested for optimal expression of these enzymes. Strains of E. coli and B.fragilis obtained from human colon will then be transformed with these plasmids and the ability of the genetically engineered bacteria to convert free ammonia and glutamine derived ammonia to citrulline will be tested initially in vitro studying bacterial cultures and then in vivo by intestinal colonization of the spfASH mouse. The expression of the transformed bacteria in culture will be investigated for enzymatic activity, ability to convert ammonia to citrulline, the effect of pH (availability of bicarbonate) and the requirement of exogenous ornithine. Subsequently, the transformed bacteria will be fed yo OTC deficient spfASH mice. The survival of the transformed bacteria in the mouse colon and the metabolic effects of this therapy will be tested with respect to ammonia metabolism and ureagenesis. The long term goal of this project is to test this therapy in humans with hyperammonemia after its efficacy and safety have been demonstrated in laboratory animals.

Project Start
1997-01-01
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ou, Li; Przybilla, Michael J; Whitley, Chester B (2018) Metabolomics profiling reveals profound metabolic impairments in mice and patients with Sandhoff disease. Mol Genet Metab :
Ou, L; Przybilla, M J; Whitley, C B (2018) SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases. Clin Genet 93:1008-1014
Ou, Li; Przybilla, Michael J; Whitley, Chester B (2017) Phenotype prediction for mucopolysaccharidosis type I by in silico analysis. Orphanet J Rare Dis 12:125
Hyland, Kendra A; Aronovich, Elena L; Olson, Erik R et al. (2017) Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters. Hum Gene Ther 28:541-550
Aronovich, Elena L; Hyland, Kendra A; Hall, Bryan C et al. (2017) Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease. Hum Gene Ther 28:551-564
Ou, Li; Przybilla, Michael J; Whitley, Chester B (2017) Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis. Mol Genet Metab 120:101-110
Verhaart, Ingrid E C; Robertson, Agata; Wilson, Ian J et al. (2017) Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis 12:124
Ou, Li; Przybilla, Michael J; Koniar, Brenda L et al. (2016) Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I. Mol Genet Metab Rep 8:87-93
Aronovich, Elena L; Hackett, Perry B (2015) Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier. Mol Genet Metab 114:83-93
Satzer, David; DiBartolomeo, Christina; Ritchie, Michael M et al. (2015) Assessment of dysmyelination with RAFFn MRI: application to murine MPS I. PLoS One 10:e0116788

Showing the most recent 10 out of 92 publications